Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Navarini AA, Zheng M, Xu J, Turki H, Anadkat MJ, Rajeswari S, Hua H, Vulcu SD, Hall D, Tetzlaff K, Thoma C, Lebwohl MG; Effisayil 1 Trial Investigators. Bachelez H, et al. Among authors: anadkat mj. N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563. N Engl J Med. 2021. PMID: 34936739 Free article. Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A, Choon SE, Bachelez H, Anadkat MJ, Marrakchi S, Zheng M, Tsai TF, Turki H, Hua H, Rajeswari S, Thoma C, Burden AD. Morita A, et al. Among authors: anadkat mj. Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5. Dermatol Ther (Heidelb). 2023. PMID: 36333618 Free PMC article.
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
Elewski BE, Lebwohl MG, Anadkat MJ, Barker J, Ghoreschi K, Imafuku S, Mrowietz U, Li L, Quaresma M, Thoma C, Bachelez H. Elewski BE, et al. Among authors: anadkat mj. J Am Acad Dermatol. 2023 Jul;89(1):36-44. doi: 10.1016/j.jaad.2023.02.040. Epub 2023 Mar 2. J Am Acad Dermatol. 2023. PMID: 36870370 Free article. Clinical Trial.
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.
Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Navarini AA, Tang M, Thoma C, Duffin KC. Burden AD, et al. Among authors: anadkat mj. Br J Dermatol. 2023 Jul 7;189(1):138-140. doi: 10.1093/bjd/ljad071. Br J Dermatol. 2023. PMID: 37075220 Free article. No abstract available.
80 results